Elevance Health, Inc. (ELV) Analyst Forecast
Revenue and earnings estimates published by analysts covering Elevance Health, Inc. (ELV), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.
For Elevance Health, Inc., analysts forecast revenue rising from $198602.78T in 2025 to $234528.00T in 2030; the average estimate for 2030 earnings per share is $46.20; with published estimates ranging from $44.48 to $47.86; 20 analysts contribute to these figures. These are forecasts published by analysts, not results.
Analyst price targets
A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.
Revenue forecast (USD millions)
The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.
Earnings per share forecast
Elevance Health, Inc. (ELV) forecast — frequently asked questions
What is the analyst price target for Elevance Health, Inc.?
Analysts covering Elevance Health, Inc. (ELV) have a consensus price target of $466.69, 7.8% above the current price of $432.86. Published targets range from $395.00 to $523.00. A price target is a forecast, not a measure of value, and targets are revised often.
What are analysts forecasting for Elevance Health, Inc.'s earnings?
The average analyst estimate for Elevance Health, Inc. (ELV) earnings per share in 2030 is 46.20, with individual estimates between 44.48 and 47.86.
How much revenue is Elevance Health, Inc. expected to make?
Analysts forecast Elevance Health, Inc. (ELV) revenue of $234528.00T in 2030, based on 5 published estimates.
How many analysts cover ELV?
20 analysts contribute estimates for Elevance Health, Inc. (ELV). Thin coverage makes an average less reliable.
Popular Stocks
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.